高级检索
当前位置: 首页 > 详情页

LncRNA DDX11 antisense RNA 1 promotes EMT process of esophageal squamous cell carcinoma by sponging miR-30d-5p to regulate SNAI1/ZEB2 expression and Wnt/beta-catenin pathway

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Hebei Med Univ, Hebei Canc Inst, Hosp 4, Shijiazhuang, Hebei, Peoples R China [2]Capital Med Univ, Beijing Shijitan Hosp, Beijing, Peoples R China
出处:
ISSN:

关键词: Esophageal squamous cell carcinoma DDX11-AS1 miR-30d-5p SNAI1 ZEB2 epithelial mesenchymal transition Wnt signaling pathway

摘要:
LncRNA DDX11 antisense RNA 1 (DDX11-AS1) is recognized as having an imperative oncogenic role in different types of human cancer. Nevertheless, the functions, as well as the basic mechanisms of DDX11-AS1 in the EMT process of esophageal squamous cell carcinoma (ESCC), are yet to be clarified. In this research, high DDX11-AS1 expression was detected in ESCC cells as well as tissues and was linked to the poor prognosis of patients with ESCC. DDX11-AS1 promoted cell proliferation, migration, invasion ability and epithelial mesenchymal transition (EMT) process in vitro. Mechanistic analysis depicted that DDX11-AS1 may function as a ceRNA through sponging miR-30d-5p to upregulate the expression of SNAI1 and ZEB2. Meanwhile, overexpression of DDX11-AS1 might cause the activation of the Wnt/beta-catenin signaling pathway via targeting miR-30d-5p. On the whole, the findings of this research illustrate that DDX11-AS1 may act as an EMT-related lncRNA to advance ESCC progression through sponging miR-30d-5p to regulate SNAI1/ZEB2 expression and activate the Wnt/beta-catenin pathway, which indicates that it might serve as a probable therapeutic target for ESCC.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2021]版:
大类 | 4 区 生物
小类 | 4 区 生物工程与应用微生物
最新[2025]版:
大类 | 4 区 生物学
小类 | 4 区 生物工程与应用微生物
JCR分区:
出版当年[2021]版:
Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
最新[2024]版:

影响因子: 最新[2024版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Hebei Med Univ, Hebei Canc Inst, Hosp 4, Shijiazhuang, Hebei, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]Hebei Med Univ, Hebei Canc Inst, Hosp 4, Shijiazhuang, Hebei, Peoples R China [*1]Hebei Cancer Institute,The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42329 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号